In addition to its role in the regulation of osteogenesis, it has been shown that the expression level of RUNX2 is higher in a variety of human cancer tissues including pancreatic, breast, colon, prostate cancers and osteosarcoma as compared with that in their corresponding normal ones, indicating that RUNX2 has an oncogenic potential [24,25,26]. Here, RUNX2 is linked to prostate cancer.